Castle Biosciences reports Q1 EPS , consensus (49c)

Reports Q1 revenue $83.7M, consensus $79.23M. “The Castle Biosciences (CSTL) team delivered outstanding results to start 2026, delivering $83.7M in revenue,” said CEO Derek Maetzold. “Our momentum this quarter reflects our robust execution and the strength of our core revenue drivers, with both DecisionDx-Melanoma and TissueCypher achieving double digit year-over-year test volume growth, 16% and 58%, respectively. As a result of our first quarter performance and continued confidence in the business, we are raising our 2026 total revenue guidance to $345M-$355M vs. the previously provided guidance of $340M-350M. In addition, during the quarter we expanded the body of evidence supporting our market-leading DecisionDx-Melanoma test…Our substantial body of evidence is a key driver of adoption and an important differentiator for DecisionDx-Melanoma and our innovative test portfolio more broadly, reinforcing our position of strength as we continue to execute across the business.”